oral tirzepatide development status Tirzepatide: First Approval | Drugs Tirzepatide Oral Rapid Dissolve Sublingual

Mller, N., Copeland, K

As a result, researchers often compare R10mg with single-target GLP-1 peptides in preclinical studies of glucose control, body weight, and metabolic function

Validation of the algorithm for longer monitoring intervals is ongoing

The study found that individuals with certain variations of Neurobeachin, called the the "sweet tooth gene" by researchers because it's associated with a preference to eat more sweets, are more likely to have success losing weight when using GLP-1 agonist medications, including Ozempic and Trulicity

10.1016/j.molmet.2022.101641 114

This aligns with standard monitoring intervals for levothyroxine therapy, typically every 3 months initially, then annually once stable